With the exception of endocrine therapy, no other systemic treatment of patients with breast cancer has reached such a magnitude of beneficial effect as trastuzumab. This targeted agent (monoclonal antibody) is associated with a significant improvement in both disease-free (DFS) and overall survival (OS) in women with HER-2 positive breast cancer when given in combination with or in sequence to adjuvant chemotherapy. This has been confirmed in a recent Cochrane meta-analysis of randomized controlled trials (RCTs), including 6 adjuvant and 2 neoadjuvant studies (NSABP B-31, NCCTG N9831, BCIRG 006, HERA, FinHer, PACS-04, Buzdar and NOAH), with data collection until February 2010. Overall, mortality is reduced by one-third and the risk of rela...
The human epidermal growth factor receptor-2 (HER2) is overexpressed and/or amplified in up to 25% o...
Trastuzumab, a monoclonal antibody against the HER2 receptor, is currently approved as a part of adj...
Overexpression of the receptor for human epidermal growth factor type 2 (HER2), or gene amplificatio...
With the exception of endocrine therapy, no other systemic treatment of patients with breast cancer ...
Background Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in adv...
BACKGROUND: Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in ad...
Among breast cancers diagnosed at any stage, 20%\u201330% are found to have HER2 gene amplification/...
Since the introduction of anti-Her2 agents, the prognosis of HER2 positive breast cancer patients si...
Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although comb...
Trastuzumab (Herceptin®) is a therapeutic monoclonal antibody (mAb) targeting the human epidermal gr...
Since the introduction of anti-Her2 agents, the prognosis of HER2 positive breast cancer patients si...
In 1985, a growth factor pathway that depends on the presence of a tyrosine kinase transmembrane rec...
In the 1980s, HER2 overexpressing tumors were recognized as a distinct subset of breast cancer, with...
Trastuzumab, a monoclonal antibody against the HER2 receptor, is currently approved as a part of adj...
[[abstract]]Objective Trastuzumab-containing treatment regimens have been shown to improve survival ...
The human epidermal growth factor receptor-2 (HER2) is overexpressed and/or amplified in up to 25% o...
Trastuzumab, a monoclonal antibody against the HER2 receptor, is currently approved as a part of adj...
Overexpression of the receptor for human epidermal growth factor type 2 (HER2), or gene amplificatio...
With the exception of endocrine therapy, no other systemic treatment of patients with breast cancer ...
Background Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in adv...
BACKGROUND: Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in ad...
Among breast cancers diagnosed at any stage, 20%\u201330% are found to have HER2 gene amplification/...
Since the introduction of anti-Her2 agents, the prognosis of HER2 positive breast cancer patients si...
Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although comb...
Trastuzumab (Herceptin®) is a therapeutic monoclonal antibody (mAb) targeting the human epidermal gr...
Since the introduction of anti-Her2 agents, the prognosis of HER2 positive breast cancer patients si...
In 1985, a growth factor pathway that depends on the presence of a tyrosine kinase transmembrane rec...
In the 1980s, HER2 overexpressing tumors were recognized as a distinct subset of breast cancer, with...
Trastuzumab, a monoclonal antibody against the HER2 receptor, is currently approved as a part of adj...
[[abstract]]Objective Trastuzumab-containing treatment regimens have been shown to improve survival ...
The human epidermal growth factor receptor-2 (HER2) is overexpressed and/or amplified in up to 25% o...
Trastuzumab, a monoclonal antibody against the HER2 receptor, is currently approved as a part of adj...
Overexpression of the receptor for human epidermal growth factor type 2 (HER2), or gene amplificatio...